These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 1725998)
1. Pharmacology of lacidipine, a vascular-selective calcium antagonist. Micheli D; Ratti E; Toson G; Gaviraghi G J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S1-8. PubMed ID: 1725998 [TBL] [Abstract][Full Text] [Related]
2. Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies. Micheli D; Collodel A; Semeraro C; Gaviraghi G; Carpi C J Cardiovasc Pharmacol; 1990 Apr; 15(4):666-75. PubMed ID: 1691398 [TBL] [Abstract][Full Text] [Related]
3. Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency. Bailey RR; Shand BI; Smith AH; Robson RA; Lynn KL Clin Nephrol; 1997 Oct; 48(4):224-9. PubMed ID: 9352156 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512 [TBL] [Abstract][Full Text] [Related]
5. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs. Sironi G; Montagna E; Greto L; Bianchi G; Leonardi A; Testa R Arzneimittelforschung; 1996 Feb; 46(2):145-52. PubMed ID: 8720303 [TBL] [Abstract][Full Text] [Related]
6. Radial artery compliance in essential hypertension: effects of antihypertensive therapy with lacidipine. Trazzi S; Santucciu C; Mancia G J Hypertens Suppl; 1993 Dec; 11(6):S17-20. PubMed ID: 8169377 [TBL] [Abstract][Full Text] [Related]
7. Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. Gin T; Joon TL; Panagiotopoulos S; Cooper M; Taylor H; Jerums G Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):281-9. PubMed ID: 8603832 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs. Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815 [TBL] [Abstract][Full Text] [Related]
10. [Preclinical study of the action of a calcium channel blocker during salt load]. Godfraind T; Salomone S; Morel N; Ghisdal P Bull Acad Natl Med; 1997 Feb; 181(2):289-98; discussion 299-300. PubMed ID: 9235228 [TBL] [Abstract][Full Text] [Related]
12. The cardiac and vascular effects of lacidipine. Agabiti-Rosei E J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S1-5. PubMed ID: 8852537 [TBL] [Abstract][Full Text] [Related]
13. [Vasodilator effects of LF 2.0254, a new 1,4-dihydropyridine. Comparison with nifedipine]. Pruneau D; Roy F; Brown NL Therapie; 1989; 44(3):203-8. PubMed ID: 2781506 [TBL] [Abstract][Full Text] [Related]
14. Antihypertensive effect of the new dihydropyridine calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedica rbo xylate hydrochloride in dogs. Okamiya Y; Kishimoto T; Sunakawa K; Aoki K; Tanabe H; Takeshita T; Naruchi T Arzneimittelforschung; 1992 Apr; 42(4):513-8. PubMed ID: 1642675 [TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effects of a new dihydropyridine calcium antagonist. Kimura Y; Fukui H; Tanaka M; Okamoto M; Morino A; Miura A; Kimura K; Enomoto H Arzneimittelforschung; 1986 Sep; 36(9):1329-35. PubMed ID: 3790182 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 1st communication: comparative studies on the cardiovascular effects of methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3- b]pyridine-5-carboxylate and its two enantiomers in experimental animals. Ueda M; Matsumura S; Masui M; Matsuura E; Uno O; Kawakami M; Ninomiya M; Adachi I Arzneimittelforschung; 1993 Dec; 43(12):1270-5. PubMed ID: 8141813 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. Rizzini P; Castello C; Salvi S; Recchia G J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S38-43; discussion S43-4. PubMed ID: 1726005 [TBL] [Abstract][Full Text] [Related]
18. Lacidipine: a review of its use in the management of hypertension. McCormack PL; Wagstaff AJ Drugs; 2003; 63(21):2327-56. PubMed ID: 14524737 [TBL] [Abstract][Full Text] [Related]
19. Lacidipine and circadian variation in blood pressure: considerations for therapy. Raftery EB J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S20-5; discussion S25-6. PubMed ID: 1726001 [TBL] [Abstract][Full Text] [Related]
20. Blood pressure-independent inhibition by lacidipine of endothelin-1-related cardiac hypertrophy in salt-loaded, stroke-prone spontaneously hypertensive rats. Feron O; Salomone S; Godfraind T J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S459-61. PubMed ID: 8587445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]